News

Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

In both the KEYNOTE-641 and KEYNOTE-789 trials, pembrolizumab, in addition to standard therapies, did not improve survival outcomes in their target populations.

A combination of immune checkpoint inhibitor and MET-targeted therapy led to high responses in patients with MET-driven papillary renal cancer, although the regimen missed its primary end point.

Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Circulating tumor DNA can be an effective biomarker that allows for assessments of early response.

At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program.

Sarah Donahue, MPH, AOCNP, cochair of the 40th Annual Miami Breast Cancer Conference nursing track, discusses the biggest updates in breast cancer from 2022.

Pure essential oils reduced the severity of chemotherapy-induced nausea and vomiting in patients receiving autologous blood and marrow transplants.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

The New Drug Application for nirogacestat has been granted priority review for the treatment of adult patients with desmoid tumors.

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.

Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia, lymphoma, and multiple myeloma.

National Donor Day happens during the month of February and is a great time to encourage people in your life to give.

Atezolizumab did not yield a significant improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Patients with papillary high-risk non-muscle-invasive bladder cancer whose disease was BCG-unresponsive showed continued antitumor activity with pembrolizumab monotherapy.

Patients with relapsed or refractory multiple myeloma experienced improved progression-free survival with idecabtagene vicleucel. Notably, cytokine release syndrome rates were high with this treatment.

Elranatamab, an investigational BCMA/CD3-targeted bispecific antibody, has received priority review status for patients with relapsed or refractory multiple myeloma.

Nurses should educate patients not only about screening guidelines, but about important cancer risks to help improve cancer prevention.

Fox Chase Cancer Center has achieved Magnet designation for nursing excellence from the American Nurses Credentialing Center (ANCC) for the sixth consecutive time.

AON celebrates its Board of Managers’ appointments and retirements.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, shares some of her top takeaways from the 2023 ASCO GI Cancers Symposium.

The FDA has granted avasopasem a priority review for severe oral mucositis in patients with head and neck cancer who are receiving radiotherapy.

Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.

Restricted diets are commonplace at many cancer centers, but there is no evidence that they reduce a patient’s risk of infection.

Real-world data support front-line maintenance with avelumab for patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy.

Updated findings from the KEYNOTE-146 trial support the use of lenvatinib/pembrolizumab in advanced endometrial cancer.

The median overall survival was 42.1 months with abiraterone plus olaparib and 34.7 months with abiraterone plus placebo in patients with metastatic castration-resistant prostate cancer.

Approximately 30% of patients remained on treatment with darolutamide for over 4 years, according to a long-term safety and tolerability updated from the ARAMIS rollover study.

At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.